Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$16.44
-$0.32 (-1.9%)
Closing Price on November 15, 2024
TEVA Articles
The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and Zynga.
Published:
Last Updated:
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Pfizer, Chesapeake Energy and other major companies reporting their quarterly results this week.
Published:
Last Updated:
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Published:
Last Updated:
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Published:
Last Updated:
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
Published:
Last Updated:
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
Published:
Last Updated:
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Published:
Last Updated:
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked...
Published:
Last Updated:
This week's top value calls from the analysts at Jefferies focus on blue chip companies that are, for the most part, very liquid and offer a degree of safety for investors.
Published:
Last Updated:
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Published:
Last Updated:
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated: